Bowen Hanes & Co’s Bristol-Myers Squibb BMY Stock Holding History

Bowen Hanes & Co’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$997K	Buy	16,445 +6,400	+64%	+$373K	0.02%	109
2025 Q4	$542K	Buy	+10,045	New	+$483K	0.01%	125
2022 Q4	–	Sell	-9,540	Closed	-$678K	–	146
2022 Q3	$678K	Sell	9,540 -50	-0.5%	-$3.63K	0.03%	118
2022 Q2	$738K	Buy	9,590 +100	+1%	+$7.62K	0.03%	118
2022 Q1	$693K	Hold	9,490	–	–	0.02%	126
2021 Q4	$592K	Hold	9,490	–	–	0.02%	129
2021 Q3	$562K	Hold	9,490	–	–	0.02%	126
2021 Q2	$634K	Hold	9,490	–	–	0.02%	118
2021 Q1	$599K	Hold	9,490	–	–	0.02%	119
2020 Q4	$589K	Sell	9,490 -47	-0.5%	-$2.89K	0.02%	115
2020 Q3	$575K	Buy	9,537 +47	+0.5%	+$2.83K	0.02%	111
2020 Q2	$558K	Hold	9,490	–	–	0.02%	109
2020 Q1	$529K	Hold	9,490	–	–	0.03%	108
2019 Q4	$609K	Hold	9,490	–	–	0.03%	119
2019 Q3	$481K	Sell	9,490 -1,250	-12%	-$58.7K	0.02%	124
2019 Q2	$487K	Sell	10,740 -2,000	-16%	-$93.2K	0.02%	122
2019 Q1	$608K	Sell	12,740 -11,500	-47%	-$573K	0.03%	113
2018 Q4	$1.26M	Buy	24,240 +13,500	+126%	+$725K	0.06%	102
2018 Q3	$667K	Sell	10,740 -65	-0.6%	-$3.86K	0.03%	110
2018 Q2	$598K	Hold	10,805	–	–	0.03%	113
2018 Q1	$683K	Hold	10,805	–	–	0.03%	111
2017 Q4	$662K	Hold	10,805	–	–	0.03%	113
2017 Q3	$689K	Hold	10,805	–	–	0.03%	113
2017 Q2	$602K	Hold	10,805	–	–	0.03%	115
2017 Q1	$588K	Buy	10,805 +300	+3%	+$16.5K	0.03%	113
2016 Q4	$614K	Sell	10,505 -6,950	-40%	-$380K	0.03%	111
2016 Q3	$941K	Hold	17,455	–	–	0.05%	101
2016 Q2	$1.28M	Hold	17,455	–	–	0.07%	88
2016 Q1	$1.11M	Sell	17,455 -1,500	-8%	-$94.6K	0.06%	91
2015 Q4	$1.3M	Hold	18,955	–	–	0.07%	93
2015 Q3	$1.12M	Hold	18,955	–	–	0.06%	108
2015 Q2	$1.26M	Buy	18,955 +100	+0.5%	+$6.59K	0.06%	105
2015 Q1	$1.22M	Sell	18,855 -104	-0.5%	-$6.51K	0.06%	107
2014 Q4	$1.12M	Buy	18,959 +404	+2%	+$22.8K	0.05%	108
2014 Q3	$950K	Sell	18,555 -1,800	-9%	-$89.9K	0.05%	117
2014 Q2	$987K	Sell	20,355 -2,325	-10%	-$115K	0.05%	111
2014 Q1	$1.18M	Buy	22,680 +1,300	+6%	+$69.2K	0.06%	107
2013 Q4	$1.14M	Sell	21,380 -1,775	-8%	-$90.4K	0.06%	105
2013 Q3	$1.07M	Hold	23,155	–	–	0.05%	102
2013 Q2	$1.03M	Buy	+23,155	New	+$1.01M	0.06%	100

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bowen Hanes & Co's BMY Position: Q1 2026 in Review

Bowen Hanes & Co increased its Bristol-Myers Squibb (BMY) stake by 64% in Q1 2026, buying an estimated $373K and bringing the position to 16,445 shares worth $997K. The position accounts for 0.02% of the portfolio, ranked #109.

Bowen Hanes & Co first reported a position in BMY in Q2 2013 and has held it in 40 quarters since. The position peaked at $1.3M in Q4 2015. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Bowen Hanes & Co held 16,445 shares of Bristol-Myers Squibb worth $997K as of Q1 2026.
Bowen Hanes & Co bought 6,400 Bristol-Myers Squibb shares in Q1 2026, an estimated $373K.
Bristol-Myers Squibb made up 0.02% of Bowen Hanes & Co's portfolio in Q1 2026, its #109 holding.
Bowen Hanes & Co first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 40 quarters since.
Bowen Hanes & Co's Bristol-Myers Squibb position peaked at $1.3M in Q4 2015.
2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Bowen Hanes & Co's 13F filing for Q1 2026, filed 14 May 2026.